CRTAM promotes antitumor immune response in triple negative breast cancer by enhancing CD8+ T cell infiltration.

[1]  M. Hung,et al.  Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer , 2021, Oncogene.

[2]  Jing Ning,et al.  Oleandrin, a cardiac glycoside, induces immunogenic cell death via the PERK/elF2α/ATF4/CHOP pathway in breast cancer , 2021, Cell Death & Disease.

[3]  M. Walter.  The Role of Structure in the Biology of Interferon Signaling , 2020, Frontiers in Immunology.

[4]  Xin Hu,et al.  Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial , 2020, Cell Research.

[5]  Y. Ho,et al.  Triple-Negative Breast Cancer: Current Understanding and Future Therapeutic Breakthrough Targeting Cancer Stemness , 2019, Cancers.

[6]  R. Schreiber,et al.  Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. , 2019, Cold Spring Harbor perspectives in biology.

[7]  Xin Hu,et al.  Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. , 2019, Cancer cell.

[8]  J. Galon,et al.  Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.

[9]  Joshua M. Korn,et al.  Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss , 2018, Nature Medicine.

[10]  L. Ivashkiv.  IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy , 2018, Nature Reviews Immunology.

[11]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[12]  Nan Zhang,et al.  PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer , 2017, International Journal of Clinical Oncology.

[13]  H. Young,et al.  Current prospects of type II interferon γ signaling and autoimmunity , 2017, The Journal of Biological Chemistry.

[14]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[15]  Xin Hu,et al.  Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value. , 2016, Cancer research.

[16]  X. Shu,et al.  Breast cancer incidence and mortality: trends over 40 years among women in Shanghai, China. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[18]  Wanqing Chen,et al.  Breast cancer in China. , 2014, The Lancet. Oncology.

[19]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[20]  H. Sinn,et al.  Triple-Negative Breast Cancer: Clinical and Histological Correlations , 2011, Breast Care.

[21]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[22]  S. Xiong,et al.  Trichosanthin enhances anti-tumor immune response in a murine Lewis lung cancer model by boosting the interaction between TSLC1 and CRTAM , 2011, Cellular and Molecular Immunology.

[23]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  V. Ortiz-Navarrete,et al.  Role of CRTAM during mouse early T lymphocytes development. , 2010, Developmental and comparative immunology.

[25]  S. Sidhu,et al.  Regulation of a Late Phase of T Cell Polarity and Effector Functions by Crtam , 2008, Cell.

[26]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[27]  K. Schroder,et al.  Interferon‐γ: an overview of signals, mechanisms and functions , 2004 .

[28]  R. Bast,et al.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. , 1991, Cancer research.

[29]  M. Djamgoz,et al.  Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. , 2018, Cancer treatment reviews.

[30]  G. Ferrara,et al.  Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. , 2018, Biochimica et biophysica acta. Reviews on cancer.